Literature DB >> 34689281

Small molecules with huge impacts: the role of miRNA-regulated PI3K pathway in human malignancies.

Bahareh Kashani1, Zahra Zandi1, Vahid Kaveh2, Atieh Pourbagheri-Sigaroodi3, Seyed H Ghaffari1, Davood Bashash4.   

Abstract

Along with evolution, a considerable number of signaling cascades have evolved within cells to meet their multifaceted needs. Among transmitting molecules, phosphoinositide 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR) have teamed up to build a signaling axis that effectively regulates various cellular processes including cell proliferation and migration. Given the extensive output of the PI3K/Akt/mTOR signaling axis, its aberrancy could subsequently lead to the formation of a wide range of human cancers spanning from hematologic malignancies to different types of solid tumors. Despite the high frequency of the PI3K pathway over-activation in most malignancies, mutations in the DNA sequence are not equally common. Such incompatibility sheds light on the possible effects of post-translational modification mechanisms that may take control of this pathway, some of the most important ones of which are through microRNAs (miRNAs or miRs). The present review is designed to take off the veil from the regulatory role of these small non-coding RNAs on the PI3K/Akt/mTOR signaling axis in carcinogenesis.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cancer; PI3K/Akt/mTOR signaling axis; Post-translational modification; miRNAs

Mesh:

Substances:

Year:  2021        PMID: 34689281     DOI: 10.1007/s11033-021-06739-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  88 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review).

Authors:  Mingli Hu; Shixuan Zhu; Shengwei Xiong; Xingxing Xue; Xiaodong Zhou
Journal:  Oncol Rep       Date:  2019-01-10       Impact factor: 3.906

Review 3.  microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer.

Authors:  Jen N Goh; Ser Y Loo; Arpita Datta; Kodappully S Siveen; Wei N Yap; Wanpei Cai; Eun M Shin; Chao Wang; Ji E Kim; Maurice Chan; Arun M Dharmarajan; Ann S-G Lee; Peter E Lobie; Celestial T Yap; Alan P Kumar
Journal:  Biol Rev Camb Philos Soc       Date:  2015-01-28

4.  Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas.

Authors:  Young Hwa Soung; Jong Woo Lee; Suk Woo Nam; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncology       Date:  2006-10-16       Impact factor: 2.935

5.  Vertebrate faunas from the Kubi Algi, Koobi Fora and Ileret areas, East Rudolf, Kenya.

Authors:  V J Maglio
Journal:  Nature       Date:  1971-05-28       Impact factor: 49.962

Review 6.  The relation between PI3K/AKT signalling pathway and cancer.

Authors:  Saeed Noorolyai; Neda Shajari; Elham Baghbani; Sanam Sadreddini; Behzad Baradaran
Journal:  Gene       Date:  2019-03-05       Impact factor: 3.688

Review 7.  PI3K-Akt pathway: its functions and alterations in human cancer.

Authors:  M Osaki; M Oshimura; H Ito
Journal:  Apoptosis       Date:  2004-11       Impact factor: 4.677

Review 8.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

Review 9.  Targeting PI3K/Akt/mTOR Signaling in Cancer.

Authors:  Camillo Porta; Chiara Paglino; Alessandra Mosca
Journal:  Front Oncol       Date:  2014-04-14       Impact factor: 6.244

Review 10.  PTEN: Multiple Functions in Human Malignant Tumors.

Authors:  Michele Milella; Italia Falcone; Fabiana Conciatori; Ursula Cesta Incani; Anais Del Curatolo; Nicola Inzerilli; Carmen M A Nuzzo; Vanja Vaccaro; Sabrina Vari; Francesco Cognetti; Ludovica Ciuffreda
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.